Followers | 37 |
Posts | 4190 |
Boards Moderated | 0 |
Alias Born | 10/18/2016 |
Friday, February 09, 2018 9:23:35 AM
A partnership between health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) and Australia’s UniQuest Pty Limited aimed at furthering research and development of a soluble gel is working toward a novel means of delivering cannabinoids to the central nervous system directly from the nasal cavity in order to treat pain, inflammation, seizures and neurological disorders. The partnership is taking advantage of the growing legalization of medical marijuana throughout the world amid increasing evidence of cannabinoids’ benefits. An article discussing this reads: “The global nasal drug delivery technology market is projected to reach $64 billion by 2021, expanding at a compound annual growth rate of 6.5 percent, according to a report issued by MarketsandMarkets (http://nnw.fm/usd0S). While the report is segmented based on dosage form, therapeutic application, end user, system, container and region, it also states ‘intranasal drug delivery is one of the most preferred drug delivery routes among patients as well as healthcare providers.’”
To view the full article, visit http://nnw.fm/S7SQn
About PreveCeutical Medical Inc.
PreveCeutical Medical Inc. is a health sciences company that develops innovative preventive therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; a Sol-gel platform for nose to brain delivery of medical compounds including cannabinoids; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). PreveCeutical sells CELLB9®, an Immune System Booster. CELLB9 is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. For more information, visit the company’s website at www.PreveCeutical.com
Recent PRVCF News
- Dual Listed Biotech Begins to Prepare POC Preclinical Study for Diabetes & Obesity Dual Gene Therapy Program • AllPennyStocks.com • 12/04/2023 01:00:00 PM
- Dual Listed Biotech Begins to Prepare POC Preclinical Study for Diabetes & Obesity Dual Gene Therapy Program • AllPennyStocks.com • 12/04/2023 01:00:00 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM